[1]孙 辉,陈英耀,任绍聪,等.非小细胞肺癌患者疾病治疗偏好与意愿支付研究[J].卫生经济研究,2018,(09):6-9.
　SUN Hui,CHEN Ying-yao,REN Shao-cong,et al.Study on Disease Treatment Preference and Willingness Payment in Patients with Non-small Cell Lung Cancer[J].Journal Press of Health Economics Research,2018,(09):6-9.
点击复制

非小细胞肺癌患者疾病治疗偏好与意愿支付研究
分享到：

卫生经济研究[ISSN:1004-7778/CN:33-1056/F]

卷:
期数:
2018年09期
页码:
6-9
栏目:
卫生技术评估
出版日期:
2018-09-04

文章信息/Info

Title:
Study on Disease Treatment Preference and Willingness Payment in Patients with Non-small Cell Lung Cancer
作者:
孙 辉1; 陈英耀1; 任绍聪1; 何露洋1; 魏 艳1; 贺 尧1; 黄 镇1
1.复旦大学公共卫生学院，卫生部卫生技术评估重点实验室，世界卫生组织卫生技术评估与管理合作中心，上海 200032
Author(s):
SUN Hui; CHEN Ying-yao; REN Shao-cong; HE Lu-yang; WEI Yan; HE Yao; HUANG Zhen
Key Laboratory of Health Technology Assessment of the Ministry of Health，School of Public Health，Fudan University，World Health Organization Center for Health Technology Assessment and Management，Shanghai 200032，China
关键词:
非小细胞肺癌; 治疗偏好; 意愿支付; 离散选择实验
Keywords:
non-small cell lung cancer;  treatment preference;  willingness to pay;  Discrete selection experiment
分类号:
R19
文献标志码:
A
摘要:
从上海、广州抽取样本医院，通过离散选择实验问卷的形式调查了非小细胞肺癌患者人群疾病治疗偏好资料，使用效应编码对不同属性及其水平进行编码，采用随机参数Logit模型进行资料分析，研究非小细胞肺癌患者对不同治疗结局的权衡偏好以及意愿支付。结果显示：患者对不同治疗结局属性偏好权重和相对重要程度排序依次为无进展生存期、乏力疲倦、给药方式、疾病控制率、恶心呕吐、皮疹；意愿支付方面，为获得11个月的无进展生存期，患者每个月愿意支付14 400元。可见，疗效是患者治疗选择首先考虑的因素，其次是治疗副作用，给药方式在影响患者治疗选择中占有一定地位。
Abstract:
This study，by discrete selection experimental questionnaires，collected data of patients' disease treatment preference with non-small cell lung cancer from sample hospitals located in Shanghai and Guangzhou. After encoding patients' attributes and levels accordingly，the random parameter Logit model was used for data analysis. This paper explored the trade-off preferences and willingness to pay for different treatment outcomes in patients with non-small cell lung cancer. The results showed that the patient's preference weight and relative importance in different treatment outcomes were ranked as following：progression-free survival，fatigue，method of drug administration，disease control rate，nausea and vomiting，rash，and patients' willingness to pay 14 400 RMB per month for 11 months of progression-free survival. It can be seen that the curative effect is the first consideration for the treatment choice of patients，followed by the side effects of treatment，and the method of drug administration plays a certain role in influencing the treatment options of patients.

参考文献/References:

[1] Dela CC, Tanoue LT, Matthay RA. Lung cancer: epidemiology, etiology, and prevention[J]. Clin Chest Med,2011,32: 605-644.
[2] Wouters H, Van Dijk L, Van Geffen ECG, Geers HCJ, Souverein PC, Bouvy ML, Stiggelbout AM. Do the benefits of statins outweigh their drawbacks? Assessing patients' trade-off preferences with conjoint analysis[J]. INTERNATIONAL JOURNAL OF CARDIOLOGY,2014,176: 1220-1222.
[3] Muehlbacher AC, Bethge S. Patients' preferences: a discrete-choice experiment for treatment of non-small-cell lung cancer[J]. EUROPEAN JOURNAL OF HEALTH ECONOMICS,2015,16: 657-670.
[4] Bridges JFP, Mohamed AF, Finnern HW, Woehl A, Hauber AB. Patients' preferences for treatment outcomes for advanced non-small cell lung cancer: A conjoint analysis[J]. LUNG CANCER,2012,77: 224-231.
[5] Muehlbacher AC, Nuebling M. Analysis of physicians' perspectives versus patients' preferences: direct assessment and discrete choice experiments in the therapy of multiple myeloma[J]. EUROPEAN JOURNAL OF HEALTH ECONOMICS,2011,12: 193-203.
[6] Catania C, Didier F, Leon ME, Sbanotto A, Mariani L, Nole F, Leida E, Rocca A, De Pas T, Goldhirsch A. Perception that oral anticancer treatments are less efficacious: development of a questionnaire to assess the possible prejudices of patients with cancer[J]. BREAST CANCER RESEARCH AND TREATMENT,2005,92: 265-272.
[7] Liu G, Franssen E, Fitch MI, Warner E. Patient preferences for oral versus intravenous palliative chemotherapy[J]. JOURNAL OF CLINICAL ONCOLOGY,1997,15: 110-115.
[8] Lee S, Glendenning P, Inderjeeth CA. Efficacy, side effects and route of administration are more important than frequency of dosing of anti-osteoporosis treatments in determining patient adherence: a critical review of published articles from 1970 to 2009[J]. OSTEOPOROSIS INTERNATIONAL,2011,22: 741-753.

相似文献/References:

[1]田梦媛,殷 潇,张欲晓,等.吉非替尼治疗晚期非小细胞肺癌的医保预算影响分析[J].卫生经济研究,2016,(12):25.
[2]孙 辉,陈英耀,何露洋,等.医生治疗非小细胞肺癌的选择偏好研究[J].卫生经济研究,2018,(09):10.
　SUN Hui,CHEN Ying-yao,HE Lu-yang,et al.Doctor's Choice Preference for Non-small Cell Lung Cancer Treatment[J].Journal Press of Health Economics Research,2018,(09):10.
[3]丁海樱,孔思思,孙 娇,等.盐酸安罗替尼用于晚期非小细胞肺癌治疗的成本效用分析[J].卫生经济研究,2020,(05):19.
　DING Hai-ying,KONG Si-si,SUN Jiao,et al.Cost-effectiveness Analysis of Anlotinib Hydrochloride for Treatment of Advanced Non-Small Cell Lung Cancer[J].Journal Press of Health Economics Research,2020,(09):19.
[4]汤雅倩,赵明烨,唐文熙.信迪利单抗对比卡瑞利珠单抗一线治疗 晚期非鳞状非小细胞肺癌的经济学评价[J].卫生经济研究,2023,40(2):34.
　TANG Yaqian,ZHAO Mingye,TANG Wenxi.Pharmacoeconomic Evaluation of Sintilimab Versus Camrelizumab in the First-Line Treatment of Patients with Non-Squamous Advanced Non-Small Cell Lung Cancer in China[J].Journal Press of Health Economics Research,2023,40(09):34.
[5]贾宇衡,杨 毅,洪立信,等.基于离散选择实验的胃癌患者治疗偏好研究[J].卫生经济研究,2025,42(04):28.
　JIA Yuheng,YANG Yi,HONG Lixin,et al.Study on Treatment Preference of Gastric Cancer Patients based on Discrete Choice Experiments[J].Journal Press of Health Economics Research,2025,42(09):28.

更新日期/Last Update: 2018-09-05